Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Ltd has seen its investment rating downgraded from Hold to Sell as of 7 May 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, flat financial trends, and concerns over quality parameters. Despite a strong stock price performance over the past year, the company faces challenges that have prompted a reassessment of its investment appeal.

Lotus Eye Hospital & Institute Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development suggests a potential shift towards a bearish trend, signalling a deterioration in the stock’s short- to medium-term momentum despite its strong long-term performance.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date perspective on its performance and outlook.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with an up-to-date view of its performance and prospects.

At Rs 121.23, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lotus Eye Hospital & Institute Ltd locked at its upper circuit of 10% on 22 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of its performance and outlook.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

At Rs 103, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lotus Eye Hospital & Institute Ltd locked at its upper circuit of 5% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 99.00, sellers were still queuing — but there were no buyers willing to take the other side. Lotus Eye Hospital & Institute Ltd locked at its lower circuit of 3.62% on 30 Mar 2026, with unfilled sell orders and a frozen price.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of its performance and prospects.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 16 Mar 2026, reflecting robust buying interest and a significant daily price gain. The stock outperformed its sector and benchmark indices despite a micro-cap status and a recent downgrade in its mojo grade, signalling renewed investor enthusiasm in the hospital sector.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date perspective on its performance and outlook.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 27 Feb 2026, propelled by robust buying interest and a significant intraday gain. The stock outperformed its sector and broader market indices, reflecting renewed investor confidence despite subdued delivery volumes and a micro-cap market capitalisation of ₹225 crores.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 23 Feb 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹112.88, down 3.94% on the day, marking a continuation of a sharp three-day decline that has wiped out over 13% of its value. This sudden drop underscores growing concerns about the company’s near-term prospects amid subdued investor participation and unfilled supply in the market.